PDIA3 and ovarian carcinoma: LYAR may be involved in the MYCN signaling pathway in the development of medulloblastoma [31] and induces neuroblastoma cell proliferation and survival [32], and LYAR together with other five genes (PDIA3, NOP14, NCALD, MTSS1, and CYP1B1) can be used as potential prognostic biomarkers for curative and postoperative supportive therapies for ovarian cancer [33].